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observed but specific treatment protocols to address this problem are sparsely reported. Standard treat-
ment includes prolonged administration of glucocorticoids as monotherapy or in combination with im-
munosuppressive drugs. The aim of this study was to assess the safety and efficacy of cytosine ara-
binoside (CA) in combination with glucocorticoids for treatment of SRMA relapses in 12 dogs on a
retrospective basis.</jats:sec><jats:sec>MethodsDogs with recurrent episodes of SRMA and treated
with a combination of CA and prednisolone were included. Information about clinical course, treatment
response and adverse events was collected from medical records. Ethical approval was not required for this
study.</jats:sec><jats:sec>ResultsTen dogs (10/12) responded well to the treatment with clinical signs
being completely controlled. One dog is in clinical remission, but still under treatment. One dog (8%)
showed further relapse. Mean treatment period was 51 weeks. Adverse events of variable severity (grade
1–4/5) were documented in all dogs during treatment according to the veterinary cooperative oncology
group grading. Three dogs developed severe adverse events. Laboratory findings showed marked changes
up to grade 4. Diarrhoea and anaemia were the most often observed adverse events (6), followed by der-
matitis (4), alopecia (3) and pneumonia (3). Including blood chemistry changes (13), 50 adverse events
were found in total.</jats:sec><jats:sec>ConclusionTreatment with CA and glucocorticoids resulted in
clinical remission in 10/12 dogs, but a high incidence of adverse events occurred requiring additional
measures. All adverse events could be managed successfully in all cases.</jats:sec>
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Evaluating the use of cytosine 
arabinoside for treatment for 
recurrent canine steroid- responsive 
meningitis- arteritis
Christian Günther   ,1 Frank Steffen,1 Daniela S Alder,1,2 Laura Beatrice,3 Caroline Geigy,3,4 
Katrin Beckmann1,3
Abstract
Background Relapses in steroid- responsive meningitis- arteritis (SRMA) are frequently observed but specific 
treatment protocols to address this problem are sparsely reported. Standard treatment includes prolonged 
administration of glucocorticoids as monotherapy or in combination with immunosuppressive drugs. The aim of 
this study was to assess the safety and efficacy of cytosine arabinoside (CA) in combination with glucocorticoids 
for treatment of SRMA relapses in 12 dogs on a retrospective basis.
Methods Dogs with recurrent episodes of SRMA and treated with a combination of CA and prednisolone were 
included. Information about clinical course, treatment response and adverse events was collected from medical 
records. Ethical approval was not required for this study.
Results Ten dogs (10/12) responded well to the treatment with clinical signs being completely controlled. One 
dog is in clinical remission, but still under treatment. One dog (8%) showed further relapse. Mean treatment 
period was 51 weeks. Adverse events of variable severity (grade 1–4/5) were documented in all dogs during 
treatment according to the veterinary cooperative oncology group grading. Three dogs developed severe adverse 
events. Laboratory findings showed marked changes up to grade 4. Diarrhoea and anaemia were the most 
often observed adverse events (6), followed by dermatitis (4), alopecia (3) and pneumonia (3). Including blood 
chemistry changes (13), 50 adverse events were found in total.
Conclusion Treatment with CA and glucocorticoids resulted in clinical remission in 10/12 dogs, but a high 
incidence of adverse events occurred requiring additional measures. All adverse events could be managed 
successfully in all cases.
Introduction
Steroid- responsive meningitis- arteritis (SRMA) is a 
well- recognised systemic inflammatory disease mainly 
affecting young, medium to large breed dogs.1 The 
acute form of SRMA is characterised by cervical rigidity, 
pain, pyrexia and a polymorphonuclear pleocytosis of 
the cerebrospinal fluid (CSF).2–4 There is no definitive 
antemortem diagnostic test for SRMA, but biomarkers 
and cytokines have been used to support the diagnosis 
and to understand the pathogenesis of SRMA.5–7 The 
precise aetiology of SRMA is still unknown. Immune- 
mediated mechanisms and dysregulated immune 
responses are suspected.2 Standard treatment consists 
of prolonged administration of glucocorticoids, 
preferably prednisolone in stepwise tapering of dosage 
during approximately six months.8 In general, the 
prognosis for SRMA is good with relapses occurring in 
16%–47.5%.9–11 A third of these cases suffer from more 
than one relapse.10 Possible reasons for relapses are 
inadequate dosage or duration of treatment.2 10
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So far little is known about treatment of SRMA 
relapses. Adjusting glucocorticoids dosage and 
duration of treatment12 or combining glucocorticoids 
with additional immunosuppressive drugs, for 
example azathioprine2 or mycophenolate mofetil,8 
have been described as therapeutic options, but studies 
investigating the efficacy and side effects are not 
sufficient.
Prolonged treatment with glucocorticoids has 
well- known side effects including diarrhoea, urinary 
incontinence, polyuria, polydipsia, cystitis, potbelly, 
alopecia, muscle atrophy, polyphagia, behaviour 
abnormalities, calcinosis cutis, gastric ulceration, 
thrombocytosis and thromboembolism.12–15 Especially 
large breed dogs seem to be prone to these side effects.16
In other canine non- infectious inflammatory 
diseases of the CNS such as meningoencephalitis of 
unknown origin (MUO) several studies have been 
published evaluating combinations of prednisolone 
with additional immunosuppressive drugs. Various 
combinations including cyclosporine, azathioprine, 
mycophenolate mofetil, cytosine arabinoside (CA), 
procarbazine, cyclophosphamide with vincristine, 
lomustine, leflunamide and radiation therapy have 
been described.17–22 No gold standard has been 
recommended. CA has been reported as an effective 
and well- tolerated treatment option with low costs for 
the treatment of MUO, but no data are available for its 
application in SRMA- relapse cases.17
The aim of this study was to assess the safety and 
efficacy of CA in combination with glucocorticoids in 
the treatment of SRMA relapses on a retrospective basis.
Material and methods
Case selection and medical records review
The medical records of the Veterinary Teaching Hospital 
of the University of Zurich were searched to identify 
dogs diagnosed with relapse of SRMA and treated with 
CA between 2011 and 2018.
Dogs were included if they had (1) complete 
medical records available; (2) clinical signs consistent 
with a relapse of SRMA (neck pain, hyperthermia and 
stiffness, leucocytosis, increased C reactive protein 
(CRP) in serum, CSF analysis with non- degenerated 
neutrophilic pleocytosis (reference interval:<5 white 
blood cells (WBCs/μL), negative analysis of infectious 
agents, initial response to glucocorticoid treatment) and 
(3) were treated for relapse with CA and prednisolone.
Dogs were excluded if medical records were not 
available, clinical signs were not consistent or if the 
relapse was not treated with CA.
Information obtained from medical records included 
signalment, duration of clinical signs before diagnosis, 
treatment received before relapse, general physical 
and neurological examination findings, and results of 
diagnostic tests including complete blood count, serum 
biochemistry profile, ancillary tests for infectious agents 
and results of cisternal CSF analysis.
Due to the retrospective character no ethical approval 
was required for this study.
Treatment and follow-up
The specific treatment protocol was recorded for 
all dogs (glucocorticoid dosage, CA dosage, route 
of administration). Following admission, all dogs 
underwent at least one daily physical and neurological 
examination by a board- certified neurologist or a 
neurology resident. Neurological examination results 
and response to treatment (improvement, deterioration 
or static) were recorded in the medical records until 
discharge.
After discharge, medical records were searched for 
re- examination or owner/vet communication to confirm 
if the dog was alive or dead and to record the current 
treatment. For those dogs managed at their referring 
practices, the veterinary surgeon was contacted directly 
via telephone or email for an update on neurological 
status, treatment course and current treatment.
All documented adverse events were graded using 
the veterinary cooperative oncology group (VCOG) 
grading system. ‘Grade 1: mild; asymptomatic or mild 
symptoms; clinical signs or diagnostic observations 
only; intervention not indicated. Grade 2: moderate; 
minimal, outpatient or non- invasive intervention 
indicated; moderate limitation of activities of daily 
living. Grade 3: severe or medically significant but 
not immediately life- threatening; hospitalisation or 
prolongation of hospitalisation indicated; disabling; 
significantly limiting activities of daily living. Grade 
4: life- threatening consequences; urgent interventions 
indicated. Grade 5: death related to adverse event’.23
Results
A total of 57 dogs diagnosed with SRMA was identified 
between 2011 and 2018. Twenty of 57 dogs (35%) 
had recurrence of clinical signs. Median age of all dogs 
presented with SRMA was 10 months (range: 3–26 
months).
Study population
Twelve dogs met the inclusion criteria. Six male dogs 
and six female dogs with relapses at a median age of 
18.5 months (range: 12–29 months) and a median 
bodyweight of 29.0 kg (range: 8.4–50 kg) were included. 
Median age at initial clinical onset of SRMA was 8 
months (range: 6–15 months). Represented breeds 
included three boxers, three Bernese mountain dogs, 
one mix- breed dog, one mastiff, one Coton de Tuléar, 
one Malinois and one Labrador retriever.
Initial clinical signs included hyperthermia, cervical 
pain with stiff gait and apathy without neurological 
deficits in all dogs. Following initial treatment with 
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Table 1 Grades and numbers of specific adverse events
CTCAE grade
Type of adverse event Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Diarrhoea 6 1
Colitis 1
Otitis externa 2   
Pyelonephritis 1
Dermatitis (all types) 4   
Cystitis 2   
Alopecia 3   
Polyuria 1   
Polydipsia 1   
Autoimmune disorders 1 (ITP)
Pneumonia 3
Fever 2 1   
Hyperpigmentation 1   
Anaemia 6 1   
Alkaline phosphatase 1 2   2
ALT 1 1 1
Lipase 1 1 1
Bilirubin 1 1   
Further diseases not classified: calcinosis cutis, lymphocytopenia, pyogranulomatous lymphadenitis.
ALT, alanine aminotransferase; CTCAE, common terminology criteria for adverse events; ITP, immune- 
mediated thrombocytopenia.
showed signs of relapse while still under treatment. The 
dogs were pretreated with prednisolone for a median 
time of 7 months (range: 1–12 months).
Four dogs (4/12) developed clinical signs 4–10 
months after cessation of the initial treatment protocol 
(mean disease- free interval: 7 months). At the time of 
relapse, the dogs were presented with neck pain (10/12), 
apathy (4/12), anorexia (2/12) and hyperthermia 
(7/12). No neurological deficits were found.
For 11/12 dogs, prednisolone monotherapy was the 
only treatment before initiation of CA with prednisolone. 
One dog had two relapses of SRMA before CA treatment 
was started. The first recurrence was treated with 
prednisolone only, but because of severe side effects, 
one month after initiation of prednisolone treatment, 
azathioprine was added in order to reduce prednisolone 
dosage. Four months after initiation of azathioprine a 
second relapse occurred under a prednisolone dosage 
of 0.5 mg/kg every 12 hours and azathioprine 2 mg/kg 
every 48 hours. Additionally, the dog had developed 
a marked increase of alanine transaminase, alkaline 
phosphatase and aspartate transaminase.
Laboratory findings
Initially CRP was measured in five dogs, the median CRP 
level was 137 mg/L (range: 0.4–257 mg/L) in serum. 
CSF analysis in all dogs revealed a non- degenerated 
neutrophilic pleocytosis with a median nucleated cell 
count of 18.9/µl (range: 0.67–3765 /µl) and a median 
protein content of 0.15 g/L (range: 0.09–2.08 g/L).
Haematology at the time of relapse revealed 
leucocytosis in 11 of 12 dogs, mainly with neutrophilic 
granulocytosis combined with monocytosis in 4 dogs. 
CRP was measured in seven dogs and ranged from 
0.7 to 137 mg/L (median: 73 mg/L). CSF analysis was 
available in 11 dogs. In 10 dogs non- degenerated 
neutrophilic pleocytosis was present. In one dog the 
CSF was normal. Leucocyte count ranged from 0 /µl to 
597 /µl (median: 42 /µl). Median CSF protein content 
was 0.22 g/L (range: 0.09–0.47 g/L).
Treatment
Treatment with prednisolone and CA was initiated 
if relapse occurred during or after prednisolone 
monotherapy or during prednisolone and azathioprine 
treatment.
Until April 2014 dogs (n=4) were treated with 
subcutaneous injections of CA (Cytosar, Pfizer PFE 
Switzerland, Zurich, Switzerland; 50 mg/m2 every 
12 hours for two consecutive days). Later, dogs (n=6) 
received CA as a constant rate of intravenous infusion 
during eight hours with a dosage of 25 mg/m2/hour, 
based upon a modification of the protocol by Lowrie 
et al.24 In the present investigation, the treatment 
protocol was shortened to three administrations every 
three weeks, followed by three administrations every 
four weeks. Afterwards three administrations every five 
weeks and finally three administrations every six weeks 
were applied.
In one dog a total of eight administrations was 
given because of owner’s preference. Median treatment 
time period was 10 months (range: 8.5–12.5 months) 
with a median of 12 CA administrations (range: 8–14 
administrations).
Additionally, the dogs received prednisolone 
(Prednisolon, Streuli Pharma AG, Uznach, Switzerland) 
following the protocol described by Cizinauskas et al.8 
Starting with an initial dosage of 4 mg/kg per day for 
two days, followed by 2 mg/kg per day for two weeks 
and afterwards 1 mg/kg for four weeks. Further dosage 
was tapered over a total of six months, depending on 
the clinical response and severity of side effects noted 
during treatment.
Response to treatment and adverse events
All owners reported a fast response within the first days 
of treatment. At the recheck three weeks after initiation 
of CA all patients showed complete resolution of clinical 
signs of SRMA.
Adverse events
Adverse events are summarised in tables 1 and 2.
Overall the grades ranged from 1 and 4. Three dogs 
developed severe adverse events requiring intensive and 
prolonged medical treatment. Grade 4 was recorded in 
laboratory findings only.
In total 50 adverse events were noted, 26 in the 
subcutaneous treated dogs and 24 in the intravenously 
treated ones. In both treatment protocols grade 4 was 
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Table 2 Listing of each patient with its adverse events
No Breed
Age at relapse, 
months Sex Weight (kg) Adverse events: VCOG- CTCAE grade (in brackets)
Further diseases while 
treatment CA protocol
1 Boxer 29 M 37.0 Diarrhoea (2), pyoderma (2), anaemia (1) None SC
2 Boxer 14 M 26.5 Diarrhoea (2), otitis externa (2), anaemia (1) None IV
3 Boxer 15 W 25.7 Anaemia (1) None SC
4 Mastiff 13 M 50.0 Pyelonephritis (3), bacterial cystitis (2), calcinosis cutis, 
dermatitis (2), lymphocytopenia, otitis externa (2), fever 
(1), AP (4), ALT (4), BUN (2), anaemia (2)
Two foreign bodies SC
5 Bernese mountain dog 27 Wk 35.0 Diarrhoea (2), bacterial cystitis (2) None SC
6 Mix- breed dog 21 M 19.5 Dermatophytosis (2) None IV
7 Bernese Mountain dog 24 W 32.4 Diarrhoea (2), alopecia (1), polyuria (1), polydipsia (1),
immune- mediated thrombocytopenia (3)
None SC
8 Coton de Tuléar 12 M 8.4 None None IV
9 Malinois 24 M 28.0 Diarrhoea (2), anaemia (1) pyogranulomatous 
lymphadenitis
None IV
10 Bernese mountain dog 18 Wk 35.6 Diarrhoea (3), colitis (3), parasitic pneumonia (3), fever (1), 
fever (2), hyperpigmentation (1), AP (4), lipase (4), ALT (3), 
BUN (1), anaemia (1)
Stomach distention after 
excessive food intake
IV
11 Bernese mountain dog 12 W 30.0
 
Diarrhoea (2), dermatitis (2), parasitic pneumonia (3), 
alopecia (1), AP (1), anaemia (1)
None SC
12 Labrador retriever 19 W 20.6 Bacterial pneumonia (3), alopecia (1), AP (2) None IV
ALT, alanine aminotransferase; AP, alkaline phosphatase; BUN, blood urea nitrogen; CA, cytosine arabinoside; CTCAE, common terminology criteria for adverse events; IV, intravenous; M, male entire; SC, 
subcutaneous; VCOG, veterinary cooperative oncology group; W, female entire; WK, female neutered.
Follow-up
The median follow- up was 27 months (range: 6–60 
months). One dog is still under treatment, receiving its 
tenth CA administration. One dog was lost to follow- up 
after finishing the CA protocol.
Follow up haematology, serum biochemistry profiles 
and/or serum CRP measurements were performed 
in an individual fashion based on the clinical status 
of the dog. Haematology was performed before the 
second administration of CA in all dogs. In six dogs 
haematology was repeated monthly. In seven dogs the 
haematocrit dropped below the reference value (<42 
%) after the first administrations but recovered during 
treatment course.
Seven months after finishing a shortened protocol 
with just eight administrations one dog showed a relapse 
with fever, stiffness and neck pain after movement. This 
dog had received CA intravenously.
No neurological deficits were found. The protocol 
was started again with prednisolone at a dosage of 
2 mg/kg every 24 hours orally and 1 mg/kg azathioprine 
every 48 hours orally. The dog showed remission of 
clinical signs and no further relapse occurred yet.
In the remaining dogs the clinical signs were 
controlled completely and no signs of SRMA recurred 
during the observation period. Available follow- up 
bloodwork of 8/12 revealed normal CRP concentrations 
and normal haematology findings.
Outcome
Ten dogs were alive at the time of publication. One dog 
was lost to follow- up after finishing the protocol and 
one dog was euthanased due to an alveolar carcinoma 
24 months after cessation of the treatment protocol.
This dog was diagnosed with immune- mediated 
thrombocytopenia six weeks before finishing CA 
protocol and received a tapering dosage of prednisolone 
for 18 months.
Discussion
Reports on treatment of recurrence of SRMA are sparse. 
This study describes a series of 12 dogs with SRMA 
relapse treated with CA and prednisolone with respect 
to response to therapy, adverse events treatment and 
long- term outcome.
Initially, dogs with SRMA respond well to treatment 
with glucocorticoids. However, the rate of relapse is 
reportedly high and ranges between 16% to 47.5%.4 10–12 
Relapses have been attributed to inadequate dosage 
or duration of treatment.2 10 Individual insensitivity 
to glucocorticoids may represent an alternative 
explanation for insufficient response to treatment. 
Glucocorticoid insensitivity has been described in 
people with asthma and other chronic inflammatory 
diseases.25 26 An insensitivity caused by interleukin 
(IL)-17/23 is described by Vazquez- Tello et al.27 
Interestingly, in human medicine the non- responding 
rate in chronic inflammatory diseases is 20%–30%,26 28 
which resembles the rate of relapses in canine SRMA. 
Reports about glucocorticoid insensitivity in chronic 
inflammatory diseases in dogs are lacking, but possible 
mechanisms have been examined in healthy dogs and 
discussed as a hypothetical explanation in dogs with 
recurring inflammatory bowel disease.29 30
In several other immune- mediated diseases such 
as immune- mediated thrombocytopenia, anaemia, 
dermatological diseases and enteropathies, a 
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outcome.31 32 Similar to SRMA, combinations of 
immunosuppressive drugs do not represent a gold 
standard but are reported to be associated with less side 
effects compared with glucocorticoid monotherapy.33–35
The treatment of SRMA relapse can be frustrating. 
Poor response, several relapses or complications 
associated with medication for SRMA can even lead 
to euthanasia in severe cases. No reliable predictive 
indicator exists for relapse- free successful therapy.8 10
Few data on how to manage SRMA relapses are 
available. Increasing prednisolone dosage and 
continuing the prednisolone protocol for a six- month 
duration resulted in complete remission of clinical 
signs in all dogs in one study, but in 25% (1/4 dogs) 
a second relapse was documented. Reported adverse 
effects in this study included diarrhoea (14/20), 
polyuria and polydipsia (13/20), weight gain (10/20) 
and polyphagia (6/20).12 In another study relapse was 
addressed by increasing the prednisolone dosage, but 
in 40% (4/10) of the cases this was not sufficient to 
control clinical signs and a second immunosuppressive 
drug was added (20 mg/kg mycophenolate mofetil 
every 48 hours). Reported side effects with this protocol 
included polyuria/polydipsia (7/9), polyphagia and 
obesity (6/9), urinary tract infection (3/9), vomiting/
diarrhoea (2/9).8 A study from North America describing 
the clinical course of SRMA stated the use of several 
second immunosuppressive drugs in 44.8% of dogs 
which showed a relapse. But no specific distinction of 
the glucocorticoid monotherapy and combined therapy 
was made.11
In the present investigation, CA was chosen as an 
add- on treatment, because it has been successfully 
applied in dogs with MUO. It is associated with mild to 
hardly any adverse events and is relatively low in price.
CA is a synthetic nucleoside, a pyrimidine analogue 
acting as an anti- metabolite. It is incorporated into 
the DNA as a false nucleoside component, leading 
to impaired DNA synthesis and cell death. CA 
penetrates the blood- brain barrier and if administrated 
intravenously as a constant rate infusion it reaches a 
significant concentration in CSF.36
In the present investigation, all dogs treated with 
prednisolone and CA showed remission of clinical 
signs of SRMA within the first weeks following the first 
administration of CA. However, this effect could also 
be attributed to the concomitant increase in dosage 
of prednisone. While Lowrie et al reported complete 
remission with increased dosage of prednisolone,12 
this was insufficient in 40% of cases reported by 
Cizinauskas et al necessitating the need for a second 
immunosuppressive drug.8
Successful outcome with no further relapse during 
a median follow- up time of 27 months was achieved in 
10/12 dogs (80%). Only in one dog (8%) another SRMA 
relapse was diagnosed eight months after cessation 
of a shortened CA protocol. This dog was treated with 
an increased dosage of prednisolone in combination 
with azathioprine. As this is the only dog in this series 
receiving a shortened protocol it is unclear if prolonged 
treatment with CA could have prevented this relapse. 
Furthermore, neither serum CRP nor CSF has been 
monitored in this dog. And also, relapses have been 
reported in dogs with normal serum CRP and CSF.10 It is 
unclear if incomplete control of the inflammation could 
have been identified using these methods and therefore 
guiding towards prolonged treatment.
None of the dogs developed neurological deficits as 
described previously in chronic cases of SRMA.4
Because CA is a chemotherapeutic drug, 
complications during therapy were recorded according 
to the common terminology criteria for adverse events 
used in veterinary oncology (VCOG- CTCAE). This 
includes reporting of all unfavourable and unintended 
signs (including abnormal clinicopathological findings), 
clinical signs or disorders temporally associated with 
the use of an anti- neoplastic agent that may or may not 
be considered related to the drug administration. While 
this allows a detailed description of events associated 
with the medication, it does not necessarily indicate 
that they are solely attributed to CA administration. All 
dogs received prednisolone together with CA and many 
of the documented adverse effects including diarrhoea, 
polyuria/polydipsia, urinary tract infection, alopecia/
hyperpigmentation have been observed at similar 
rates in long- term follow- up studies of SRMA cases 
receiving prednisolone12 or with prednisolone and 
mycophenolate8 indicating that these adverse events 
are most likely attributed to prednisolone treatment. 
Transient mild anaemia has been reported in dogs with 
MUO treated with CA and this was also detected in 7/12 
dogs in this study suggesting a possible association 
with CA administration.24
Other adverse events such as pneumonia secondary 
to Angiostrongylus vasorum infection may be related to 
insufficient immunoreaction due to prednisolone and/
or CA treatment, but in endemic areas this may also 
reflect insufficient parasitic prophylaxis.
Another interesting finding of this study was the 
presence of additional immune- mediated diseases in 
6/12 dogs (50%) including atopic dermatitis (5/12) and 
immune- mediated thrombocytopenia (1/12).
The use of CA and prednisolone in dogs with MUO 
was associated with mild side effects only. In contrast, 
adverse effects were observed more frequently and 
were more severe in the present investigation. There 
are several hypotheses to explain this difference. While 
MUO is restricted to the CNS, SRMA has a more systemic 
nature and the immune system in general seems to 
be dysregulated. Another explanation may be the 
signalment of dogs with SRMA that are substantially 
larger (median bodyweight of 29 kg in the present study) 
compared with dogs with MUO (typically small breed 
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of steroids may result in more clinically relevant side 
effects.37 Possibly using the body surface as a basis 
for the calculation of the prednisolone dosage instead 
of the bodyweight, some of the side effects could 
be reduced as suggested in a recent publication.37 A 
third reason might be different reporting schemes: 
while in the present study all clinical and laboratory 
abnormalities were reported during treatment, previous 
studies mainly included adverse events clearly related 
to the administration of CA.
In one recent study the VCOG grading system was 
applied, but only to the haematological abnormalities.38 
Post- treatment haematology changes ranging from 
grade 1 to grade 2 were found in 4/49 (8%) samples 
in MUO cases.38 In contrast 17/56 (30%) grade 1 
abnormalities in the samples of the dogs with SRMA 
included in the present study were identified, supporting 
higher incidence of adverse events in dogs with SRMA 
compared with dogs with MUO.
However, a greater understanding of the 
immunopathogenesis of SRMA may lead to alternative 
treatment options with less side effects in this 
common but still not adequately controlled disorder. 
Investigating the cytokine pathways3 6 39 40 and influence 
of the endocannabinoid system on the inflammatory 
response in dogs with SRMA,41 a dysregulation of 
several cytokines including IL-23 and IL-17 was found. 
These two cytokines seem to play a major role in SRMA, 
and in other immune- mediated diseases in dogs such 
as inflammatory bowel disease, asthma and chronic 
inflammatory arthritis.42–44 These data indicate the need 
of further research in the area of immune- mediated 
diseases in dogs and their management.
Limitations of this study are primarily related to its 
retrospective character, the small study population, 
absence of a control group and the use of two different 
routes of CA administration. A prospective randomised 
study design using different treatment protocols 
would be necessary to eliminate flaws and biases and 
to compare safety and efficacy of different treatment 
protocols in order to provide more robust results. 
Based upon the benefit and relative safety of the 
presented treatment protocol it can be recommended 
as management for SRMA relapses until more evidence- 
based studies are available.
In the present study SRMA relapses were 
successfully controlled in all dogs and further relapses 
were prevented in 11/12 dogs. None of the dogs 
were euthanased or died because of the disease or 
complications associated with treatment. However, in 
all dogs, adverse events in various degrees of severity 
were observed. Based upon these results, this treatment 
protocol can be recommended as an effective treatment 
option but monitoring of the patients is required to 
recognise and control adverse events.
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